Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients ...

Tempus AI TEM is leaning into a dual-engine model: a fast-growing Genomics franchise and a scaling data business powered by an expanding AI toolkit. The third quarter of 2025 marked a turn to non-GAAP ...

Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient ...

The Diagnostics segment of Tempus AI TEM experienced strong growth in 2025, driven primarily by increasing adoption of precision oncology testing and its integration of artificial intelligence with ...

TEM's diagnostics arm surges on oncology demand, MRD adoption and rising pricing, with 2026 growth set to stay strong as ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in MRD testing, announced findings presented this week at the European Society of Medical Oncology Congress (ESMO) Congress ...

Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung ...